SCHOTT Pharma KGaA Dividends and Buybacks
Dividend criteria checks 1/6
SCHOTT Pharma KGaA is a dividend paying company with a current yield of 1.29% that is well covered by earnings.
Key information
1.3%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 1.4% |
| Dividend Growth | 10.6% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 18% |
Recent dividend and buyback updates
Recent updates
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 14
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
Feb 02SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
Dec 15A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Nov 24Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Nov 02Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
Sep 19Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Aug 15These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Jul 19Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
Jun 13Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 18An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Apr 27We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Mar 22SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
Feb 12Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Jan 13
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Nov 25SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
Oct 27SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Sep 01Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Aug 07Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, 1SXP has been paying a dividend for less than 10 years.
Growing Dividend: 1SXP's dividend payments have increased, but the company has only paid a dividend for 2 years.
Dividend Yield vs Market
| SCHOTT Pharma KGaA Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (1SXP) | 1.3% |
| Market Bottom 25% (DE) | 1.6% |
| Market Top 25% (DE) | 4.6% |
| Industry Average (Life Sciences) | 0.9% |
| Analyst forecast (1SXP) (up to 3 years) | 1.4% |
Notable Dividend: 1SXP's dividend (1.29%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.64%).
High Dividend: 1SXP's dividend (1.29%) is low compared to the top 25% of dividend payers in the German market (4.6%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (18.2%), 1SXP's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (242.6%), 1SXP's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 18:03 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Christian Ehmann | Berenberg |